{
    "nctId": "NCT00383604",
    "briefTitle": "Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2",
    "officialTitle": "Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2",
    "overallStatus": "COMPLETED",
    "conditions": "Lymphedema, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "assess insulin sensitivity in late breast cancer survivors",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients enrolled in the proposed studies must be survivors of breast cancer at a time point at least 4 years following the initial surgery and radiotherapy for the disease.\n* Patients must have a history of unilateral axillary lymph node dissection.\n* Patients referred to, or that receive their care within the Stanford University Breast Cancer Program and the Stanford Center for Lymphatic and Venous Disorders.\n* Patients will be required to have the capacity to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate.\n* Patients will not be enrolled if they are taking drugs that affect carbohydrate metabolism.\n* Patients with recurrent breast cancer or other forms of pre-existing lymphedema will be ineligible.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}